Skip to main content
Cirle A Warren on Muck Rack

Cirle A Warren

As seen in: Wiley Online Library, BMJ Open, Journal of Infection
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Cirle A

Contact Cirle A, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Multi-strain Clostridioides difficile infection: Increased Detection and Clinical Implications

|
By Jae Hyun Shin, Maria L.G.S. Morais, Newport Beach, Katia Sol-Church, Pankaj Kumar Verified, Cirle A Warren, Mônica J. Rodrigues-Jesus, Guruprasad V. Konduru, Deiziane V.S. Costa
| Journal of Infection Verified
Keywords Multi-strains Clostridioides difficile infection Non-toxigenic strains Severity of disease Introduction Clostridioides difficile (C. difficile) is a gram-positive, anaerobic, spore-forming bacterium and the causative agent of C. difficile infection (CDI). C. difficile is the leading cause of hospital-associated diarrhea worldwide 1,2. Moreover, cases of community-acquired CDI have been increasing 3.
Open in Who Shared Issue with article?

A Low Concentration of Butyrate has a Protective Action Against the Deleterious Effects of Clostridioides difficile Toxins on Enteric Glia

|
By Cirle A Warren, Andrea V. Loureiro
| Wiley Online Library Verified
Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description jbt70475-sup-0001-Sousa_et_al_supplementary_data.docx32.7 KB Table 1: Primers used in qPCR analysis. References 1 and , “The Role of Toxins in Clostridium difficile Infection,” FEMS Microbiology Reviews 41 (2017): 723–750. 2, et al., “An Update on Clostridioides difficile Binary Toxin,” Toxins (Basel) 14 (2022): 1–13.
Open in Who Shared Issue with article?

Alanyl-glutamine supplementation for Clostridioides difficile infection treatment (ACT): a double-blind randomised controlled trial study protocol

|
By Jae Hyun Shin, Xin Wang, Cirle A Warren, Ekta N Bansal
| BMJ Open Verified
Methods and analysis Study design This is a phase II, randomised, double-blinded, placebo controlled clinical trial in adult patients with non-severe or severe uncomplicated CDI. It is designed to test the hypothesis that compared with standard of care, daily AQ supplementation will reduce recurrence (primary outcome) and mortality (secondary outcome) during 60 days post-treatment follow-up.
Open in Who Shared View Duplicates (2) Issue with article?
See all 3 articles